Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetic Profile of CTP-692 in Fed and Fasted Conditions in Healthy Volunteers

Next Previous
Trial Profile

A Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetic Profile of CTP-692 in Fed and Fasted Conditions in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Dec 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deutarserine (Primary)
  • Indications CNS disorders; Schizophrenia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Concert Pharmaceuticals

Most Recent Events

  • 01 Aug 2019 According to a Concert Pharmaceuticals media release,data from this study will be presented during a poster session at the European College of Neuropsychopharmacology Congress taking place September 7-10, 2019 in Copenhagen, Denmark.
  • 12 Jun 2019 Topline results published in the Concert Pharmaceuticals Media Release
  • 02 May 2019 According to a Concert Pharmaceuticals media release, the trial was completed in the first quarter of 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top